RedShift BioAnalytics develops and commercializes a novel analytical platform, Microfluidic Modulation Spectroscopy (MMS), for detecting pivotal changes in molecular structure. Its flagship AQS3pro instrument delivers fully automated, ultrasensitive, and ultraprecise measurements of secondary structure for proteins, mRNA, AAVs, ADCs, mAbs, and other biomolecules. The company reports a rapidly growing list of user publications demonstrating broad utility across drug discovery, development, formulation, and quality control. RedShiftBio has sold instruments to the majority of leading biopharmaceutical companies in North America, Europe, and Asia. It recently opened the StructurIR Scientific Services Lab to provide institutions access for sample testing and proof-of-concept experiments. The company will use the new financing to fund additional commercial expansion, continue technology innovation, and execute product development objectives. Headquartered in Burlington, Massachusetts, RedShiftBio positions MMS as a tool for supporting biotherapeutics and vaccine development worldwide. RedShift BioAnalytics develops analytical instrumentation and a patented Microfluidic Modulation Spectroscopy (MMS) technique to probe protein secondary structure for biotherapeutic development. Its flagship AQS3pro infrared platform offers advanced data analytics and direct measurement of previously undetectable changes in protein structural attributes, replacing the need for multiple instruments. The company reports successful launch of the AQS3pro and installation of its first production systems at three major biopharmaceutical companies in the US and Europe. Management expects rapid commercial growth and has appointed Julien Bradley as CEO to lead expansion; Chip Marshall will remain as COO. RedShiftBio completed an oversubscribed $18M Series D Preferred Stock financing to support commercial expansion and continued innovation. The company targets improved decision-making across discovery, formulation and manufacture of protein therapeutics. RedShift BioAnalytics develops bioanalytical instruments for the R&D and manufacturing of protein-based therapeutics. Its platform combines innovative lasers, microfluidics and analytical technologies to deliver five critical measurements: quantitation, structure, stability, aggregation and similarity. The company is led by CEO Chip Marshall. In March 2017 it closed a financing to support commercialization efforts. RedShift says it will use the funds to accelerate commercialization of its biotechnology instrument platform in 2017. The business targets customers involved in protein therapeutic development and manufacturing. RedShift Systems develops infrared tunable filter technology, offering micro-optical tunable infrared filters that are solid-state devices with no moving parts. Its core products enable compact tunable components and systems for infrared spectroscopy. The company is entering the molecular spectroscopy market with a family of tunable infrared lasers that it says offer performance improvements over conventional FTIR-based solutions. RedShift intends to use new capital to increase adoption of its filters and lasers across existing and emerging infrared spectroscopy markets. The company is led by Chip Marshall (CEO) and Eugene Ma, Ph.D. (CTO and co-founder).

Total raised

$52M

Funding rounds

4

Latest round

Series E

Latest activity

Oct 2021